Onureg is a cancer medicine used to treat acute myeloid leukaemia (AML), a cancer of white blood cells. It is used for maintenance treatment after the initial cancer treatment has brought the disease under control, in patients who cannot be given haematopoietic stem cell transplantation (a procedure to replace the cells that produce blood cells) to prevent the cancer coming back. Onureg contains the active substance azacitidine.
Therapeutic Indication
### Therapeutic indication Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).
Therapeutic Area (MeSH)
ATC Code
L01BC07
ATC Item
azacitidine
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| azacitidine | N/A | 阿扎胞苷 |
EMA Name
Onureg
Medicine Name
Onureg
Aliases
N/A